Leveraging genomic data in smoking cessation trials in the era of precision medicine: Why and how

Nicotine and Tobacco Research

Volumn 20, Issue 4, 2018, Pages 414-424

  Chen, Li Shiun ^a   Zawertailo, Laurie ^b   Piasecki, Thomas M ^c   Kaprio, Jaakko ^d   Foreman, Marilyn ^e   Elliott, Hannah R ^f   David, Sean P ^g   Bergen, Andrew W ^h   Baurley, James W ^h   Tyndale, Rachel F ^b   Baker, Timothy B ⁱ   Bierut, Laura J ^a   Saccone, Nancy L ^j   Relton, Caroline ^k  

^a Washington University in St Louis School of Medicine   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MISSOURI   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e MOREHOUSE SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Biorealm   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; COTININE; NICOTINE PATCH; PLACEBO; VARENICLINE;

BIOBANK; CHRNA5 GENE; CONFIDENTIALITY; GENE; GENETIC MARKER; GENETIC SCREENING; GENOMICS; HUMAN; INFORMED CONSENT; NICOTINE REPLACEMENT THERAPY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PRIVACY; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE; CLINICAL TRIAL (TOPIC); GENETICS; META ANALYSIS; PROCEDURES; PSYCHOLOGY; SMOKING;

CLINICAL TRIALS AS TOPIC; GENOMICS; HUMANS; PRECISION MEDICINE; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION DEVICES; TOBACCO USE DISORDER;

EID: 85043580891     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntx097     Document Type: Review

References (95)

1. Schroeder SA. New evidence that cigarette smoking remains the most important health hazard. N Engl J Med. 2013;368(4):389-390.
2. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351-364.
3. Whiteford HA, Baxter AJ. The Global Burden of Disease 2010 study: what does it tell us about mental disorders in Latin America? Rev Bras Psiquiatr. 2013;35(2):111-112.
4. Knopik VS, Maccani MA, Francazio S, McGeary JE. The epigenetics of maternal cigarette smoking during pregnancy and effects on child development. Dev Psychopathol. 2012;24(4):1377-1390.
5. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341-350.
6. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services, U.S. Public Health Service;2008.
7. Centers for Disease Control and Prevention. Current cigarette smoking among adults -United States, 2011. Morbidity and Mortality Weekly Report. 2012;61(44):889-894.
8. Vaidyanathan G. Redefining clinical trials: the age of personalized medicine. Cell. 2012;148(6):1079-1080.
9. McMahon FJ, Insel TR. Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron. 2012;74(5):773-776.
10. Gold AB, Lerman C. Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet. 2012; 131(6):857-876.
11. Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol Med. 2010;16(7-8):247-253.
12. Uhl GR, Drgon T, Johnson C, Ramoni MF, Behm FM, Rose JE. Genomewide association for smoking cessation success in a trial of precessation nicotine replacement. Mol Med. 2010;16(11-12):513-526.
13. McGeary JE, Knopik VS, Hayes JE, Palmer RH, Monti PM, Kalman D. Predictors of relapse in a bupropion trial for smoking cessation in recentlyabstinent alcoholics: preliminary results using an aggregate genetic risk score. Subst Abuse. 2012;6:107-114.
14. David SP, Strong DR, Leventhal AM, et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction. 2013;108(12):2202-2211.
15. NIH. Precision Medicine Initiative. 2015; http://www.nih.gov/ precisionmedicine/.
16. Young RP, Hopkins RJ, Gamble GD. Clinical applications of gene-based risk prediction for lung cancer and the central role of chronic obstructive pulmonary disease. Front Genet. 2012;3:210.
17. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
18. Roychowdhury S, Chinnaiyan AM. Translating genomics for precision cancer medicine. Annu Rev Genomics Hum Genet. 2014;15:395-415.
19. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-4253.
20. International Association for the Study of Lung Cancer (IASLC) Association for Molecular Pathology (AMP). Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors, Summary of recommendations. https://www.iaslc.org/sites/ default/files/wysiwyg-assets/cap_iaslc_amp_summary_of_recommendations. pdf. Accessed November 22, 2015.
21. Bergen AW, Javitz HS, Krasnow R, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics. 2013;23(2):94-103.
22. Chen LS, Baker TB, Jorenby D, et al. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend. 2015;154:278-282.
23. Chen LS, Baker TB, Piper ME, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry. 2012;169(7):735-742.
24. Chen LS, Bloom AJ, Baker TB, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction. 2014;109(1):128-137.
25. Lerman C, Schnoll RA, Hawk LW Jr, et al.; PGRN-PNAT Research Group. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015;3(2):131-138.
26. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
27. Kimmel SE, French B, Kasner SE, et al.; COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283-2293.
28. FDA. Genomics -table of pharmacogenomic biomarkers in drug labeling. 2015. Retrieved from https://www.fda.gov/drugs/scienceresearch/ researchareas/pharmacogenetics/ucm083378.htm
29. Mallal S, Phillips E, Carosi G, et al.; PREDICT-1 Study Team. HLAB*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579.
30. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-1143.
31. Relling MV, Gardner EE, Sandborn WJ, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89(3):387-391.
32. Bainbridge MN, Wiszniewski W, Murdock DR, et al. Whole-genome sequencing for optimized patient management. Sci Transl Med. 2011;3(87):87re3.
33. Worthey EA, Mayer AN, Syverson GD, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2011;13(3):255-262.
34. Teutsch SM, Bradley LA, Palomaki GE, et al.; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med. 2009;11(1):3-14.
35. Metzker ML. Sequencing technologies -the next generation. Nat Rev Genet. 2010;11(1):31-46.
36. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12(2):87-98.
37. Wang JC, Cruchaga C, Saccone NL, et al.; COGEND collaborators and GELCC collaborators. Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet. 2009;18(16):3125-3135.
38. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet. 2010;11(3):191-203.
39. Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet. 2009;10(10):669-680.
40. Altelaar AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2013;14(1):35-48.
41. Shulaev V. Metabolomics technology and bioinformatics. Brief Bioinform. 2006;7(2):128-139.
42. Hurko O. The uses of biomarkers in drug development. Ann N Y Acad Sci. 2009;1180:1-10.
43. Bough KJ, Lerman C, Rose JE, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther. 2013;93(6):526-538.
44. Institute of Medicine. Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: National Academies Press; 2011.
45. Wan ES, Qiu W, Baccarelli A, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet. 2012;21(13):3073-3082.
46. Zeilinger S, Kühnel B, Klopp N, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One. 2013;8(5):e63812.
47. Zhang Y, Yang R, Burwinkel B, Breitling LP, Brenner H. F2RL3 methylation as a biomarker of current and lifetime smoking exposures. Environ Health Perspect. 2014;122(2):131-137.
48. Nishita DM, Jack LM, McElroy M, et al. Clinical trial participant characteristics and saliva and DNA metrics. BMC Med Res Methodol. 2009;9:71.
49. Swan GE, Javitz HS, Jack LM, et al. Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes. Pharmacogenomics J. 2012;12(4):349-358.
50. Institute-of-Medicine. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: National Academies Press). Institute of Medicine of the National Academies; 2011.
51. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2009;92(1):6-11.
52. Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther. 2010;87(3):351-355.
53. McClure JB, Swan GE, St John J, et al. Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study. Nicotine Tob Res. 2013;15(2):518-526.
54. Baker TB, Collins LM, Mermelstein R, et al. Enhancing the effectiveness of smoking treatment research: conceptual bases and progress. Addiction. 2016;111(1):107-116.
55. Collins LM, Trail JB, Kugler KC, Baker TB, Piper ME, Mermelstein RJ. Evaluating individual intervention components: making decisions based on the results of a factorial screening experiment. Transl Behav Med. 2014;4(3):238-251.
56. Hartz SM, Johnson EO, Saccone NL, Hatsukami D, Breslau N, Bierut LJ. Inclusion of African Americans in genetic studies: what is the barrier? Am J Epidemiol. 2011;174(3):336-344.
57. NIDA. NIDA Genetics Consortium. https://www.drugabuse.gov/aboutnida/ organization/workgroups-interest-groups-consortia/genetics-workgroup-gwg/nida-genetics-consortium-ngc. Accessed May 22, 2016.
58. Baurley JW, Edlund CK, Pardamean CI, Conti DV, Bergen AW. Smokescreen: a targeted genotyping array for addiction research. BMC Genomics. 2016;17:145.
59. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44(6):588-597.
60. Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EP. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. preventive services task force. Ann Intern Med. 2015;163(8):608-621.
61. Fagerström K, Russ C, Yu CR, Yunis C, Foulds J. The Fagerström test for nicotine dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res. 2012;14(12):1467-1473.
62. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105-3124.
63. TAG. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. May 2010;42(5):441-447.
64. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al.; ENGAGE Consortium. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5):448-453.
65. Liu JZ, Tozzi F, Waterworth DM, et al.; Wellcome Trust Case Control Consortium. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42(5):436-440.
66. Saccone NL, Culverhouse RC, Schwantes-An TH, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a metaanalysis and comparison with lung cancer and COPD. PLoS Genet. 2010;6(8) pii: e1001053.
67. Hedeker D, Mermelstein RJ, Demirtas H. Analysis of binary outcomes with missing data: missing = smoking, last observation carried forward, and a little multiple imputation. Addiction. 2007;102(10):1564-1573.
68. Rubin DB. Multiple imputation after 18+ years. J Am Statist Assoc. 1996;91(434):473-489.
69. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25.
70. Kalman LV, Agúndez J, Appell ML, et al. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther. 2016;99(2):172-185.
71. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17(3):279-301.
72. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100(3):299-303.
73. Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: a meta-analysis. Addict Behav. 2008;33(12):1516-1520.
74. Ferguson SG, Gitchell JG, Shiffman S. Continuing to wear nicotine patches after smoking lapses promotes recovery of abstinence. Addiction. 2012;107(7):1349-1353.
75. Shiffman S, Scharf DM, Shadel WG, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol. 2006;74(2):276-285.
76. Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB. The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. J Consult Clin Psychol. 2011;79(1):34-42.
77. Baker TB, Mermelstein R, Collins LM, et al. New methods for tobacco dependence treatment research. Ann Behav Med. 2011;41(2):192-207.
78. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Baker TB. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction. 2008;103(9):1521-1533.
79. Brandon TH, Vidrine JI, Litvin EB. Relapse and relapse prevention. Annu Rev Clin Psychol. 2007;3:257-284.
80. Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol. 1996;64(2):366-379.
81. Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs. 2010;70(18):2357-2372.
82. Schmitz JM, Stotts AL, Mooney ME, Delaune KA, Moeller GF. Bupropion and cognitive-behavioral therapy for smoking cessation in women. Nicotine Tob Res. 2007;9(6):699-709.
83. Bolt DM, Piper ME, Theobald WE, Baker TB. Why two smoking cessation agents work better than one: role of craving suppression. J Consult Clin Psychol. 2012;80(1):54-65.
84. Perkins KA, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl). 2006;184(3-4):628-636.
85. Brown RA, Burgess ES, Sales SD, Whiteley JA, Evans DM, Miller IW. Reliability and validity of a smoking timeline follow-back interview. Psychology of Addictive Behaviors. 1998;12:101-112.
86. Shiffman S. How many cigarettes did you smoke? Assessing cigarette consumption by global report, time-line follow-back, and ecological momentary assessment. Health Psychol. 2009;28(5):519-526.
87. Hamilton CM, Strader LC, Pratt JG, et al. The PhenX toolkit: get the most from your measures. Am J Epidemiol. 2011;174(3):253-260.
88. Snyder CF, Watson ME, Jackson JD, Cella D, Halyard MY; Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Patient-reported outcome instrument selection: designing a measurement strategy. Value Health. 2007;10 Suppl 2:S76-S85.
89. Edelen MO. The PROMIS smoking assessment toolkit-background and introduction to supplement. Nicotine Tob Res. 2014;16 Suppl 3:S170-S174.
90. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638-642.
91. David SP, Hamidovic A, Chen GK, et al. Genome-wide meta-analyses of smoking behaviors in African Americans. Transl Psychiatry. 2012;2:e119.
92. Loukola A, Buchwald J, Gupta R, et al. A genome-wide association study of a biomarker of nicotine metabolism. PLoS Genet. 2015;11(9):e1005498.
93. David SP, Bergen AW, Munafo M, Schuit E, Bennett DA. Genomic analysis to guide choice of treatment for smoking cessation. Cochrane Database Syst Rev. 2015.
94. Rutter JL. Symbiotic relationship of pharmacogenetics and drugs of abuse. AAPS J. 2006;8(1):E174-E184.
95. Chen LS, Baker TB, Grucza R, et al. Dissection of the phenotypic and genotypic associations with nicotinic dependence. Nicotine Tob Res. 2012;14(4):425-433.